HDAC6 score: to treat or not to treat?

Developing approaches to identify patients who may benefit from specific treatments is an important area of research. A study now defines an HDAC6 score to predict the response of patients with breast cancer to the HDAC6 inhibitor ricolinostat and characterizes its anti-tumor effects with preclinical mechanistic work and a phase 1b clinical trial.

Automated summary

Developing methods to identify patients who may benefit from specific treatments is crucial. A recent study has established an HDAC6 score to predict how patients with breast cancer will respond to the HDAC6 inhibitor ricolinostat. The study also investigates the anti-tumor effects of the inhibitor through preclinical mechanistic work and a phase 1b clinical trial.